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Abstract
Muscarinic receptor agonists have primarily been used to characterize endothelium-dependent
vasodilator dysfunction with overweight/obesity. Reliance on a single class of agonist, however,
yields limited, and potentially misleading, information regarding endothelial vasodilator capacity.
The aims of this study were to determine 1) whether the overweight/obesity-related reduction in
endothelium-dependent vasodilation extends beyond muscarinic receptor agonists and 2) whether
the contribution of nitric oxide (NO) to endothelium-dependent vasodilation is reduced in
overweight/obese adults. Eighty-six middle-aged and older adults were studied: 42 normal-weight
(54 ± 1 yr, 21 men and 21 women, body mass index = 23.4 ± 0.3 kg/m2) and 44 overweight/obese
(54 ± 1 yr, 28 men and 16 women, body mass index = 30.3 ± 0.6 kg/m2) subjects. Forearm blood
flow (FBF) responses to intra-arterial infusions of acetylcholine in the absence and presence of the
endothelial NO synthase inhibitor NG-monomethyl-L-arginine, methacholine, bradykinin,
substance P, isoproterenol, and sodium nitroprusside were measured by strain-gauge
plethysmography. FBF responses to each endothelial agonist were significantly blunted in the
overweight/obese adults. Total FBF (area under the curve) to acetylcholine (50 ± 5 vs. 79 ± 4 ml/
100 ml tissue), methacholine (55 ± 4 vs. 86 ± 5 ml/100 ml tissue), bradykinin (62 ± 5 vs. 85 ± 4
ml/100 ml tissue), substance P (37 ± 4 vs. 57 ± 5 ml/100 ml tissue), and isoproterenol (62 ± 4 vs.
82 ± 6 ml/100 ml tissue) were 30%–40% lower in the overweight/obese than normal-weight
adults. NG-monomethyl-L-arginine significantly reduced the FBF response to acetylcholine to the
same extent in both groups. There were no differences between the groups in the FBF responses to
sodium nitroprusside. These results indicate that agonist-stimulated endothelium-dependent
vasodilation is universally impaired with overweight/ obesity. Moreover, this impairment appears
to be independent of NO.
Keywords
cell surface receptors; intracellular signaling pathways; nitric oxide
Copyright © 2008 the American Physiological Society
Address for reprint requests and other correspondence: C. A. DeSouza, Dept. of Integrative Physiology, Univ. of Colorado, 354 UCB,
Boulder, CO 80309 (desouzac@colorado.edu).
NIH Public Access
Author Manuscript
Am J Physiol Heart Circ Physiol. Author manuscript; available in PMC 2013 June 19.
Published in final edited form as:













Impaired endothelium-dependent vasodilation, a hallmark characteristic of endothelial
dysfunction, has been linked etiologically to the initiation and development of
atherosclerotic vascular disease (25, 35). Indeed, reduced endothelium-mediated
vasodilation occurs early in atherogenesis, before histological and/or angiographic evidence
of disease (38). Endothelial function, particularly endothelium-dependent vasodilation, is
impaired in overweight and obese adults and is thought to contribute to their increased risk
of coronary artery disease, cerebrovascular disease, and atherothrombotic events (23, 24, 29,
30, 32)
The mechanisms responsible for the adiposity-related reduction in endothelial vasodilator
function in adult humans are not completely understood. Pharmacological studies have
primarily employed muscarinic receptor agonists, acetylcholine or methacholine, to assess
the influence of increased body fatness on endothelium-dependent vasodilation (23, 30, 31).
The reliance on a single agonist, however, yields limited, and potentially misleading,
information regarding endothelial vasodilator capacity. For example, we previously
demonstrated that although the forearm vasodilator response to acetylcholine declines with
advancing age, the vascular responses to other agonists, including bradykinin, substance P,
and isoproterenol, are well preserved (9). Moreover, in hypercholesterolemic patients,
forearm vasodilation to acetylcholine and substance P, but not bradykinin, has been shown
to be blunted (6, 14). Thus the use of multiple agonists is a more rigorous approach to assess
endothelial vasodilator capacity in conscious humans, inasmuch as it provides additional
insight into the extent, degree, and potential mechanism of dysfunction. It is unknown
whether the endothelial vasodilator dysfunction observed in overweight and obese adults is
limited to muscarinic receptor agonists.
Accordingly, the primary experimental aim of the present study was to determine whether
the overweight/obesity-related reduction in endothelium-dependent vasodilation extends
beyond muscarinic receptor agonists. To address this aim, we determined the forearm
vascular responses to a variety of endothelial agonists that stimulate nitric oxide (NO)-
mediated vasodilation via different cell surface receptors and intracellular signaling
pathways in normal-weight and overweight/obese adults. A secondary aim was to determine




Eighty-six middle-aged and older adults (41–71 yr of age) were studied: 42 were normal
weight [body mass index (BMI) ≤25.0 kg/m2] and 44 were overweight/obese (BMI = 27.0–
40.0 kg/m2). All subjects were sedentary and had not participated in a regular aerobic
exercise program for ≥2 yr before the start of the study. Subjects were excluded from the
study if they presented a history or evidence of hepatic, renal, or hematologic disease;
peripheral vascular disease; stroke; diabetes (fasting plasma glucose >7.0 mmol/l) (2); dysli-
poproteinemia (total cholesterol ≥6.0 mmol/l, triglycerides ≥3.0 mmol/l) (11); or
hypertension (blood pressure ≥ 140/90 mmHg) (7). All subjects were screened for clinical
evidence of coronary artery disease with resting and maximal-exercise electrocardiograms
and blood pressure. None of the subjects smoked or were taking medication, including
vitamins. All the women were ≥1 yr (mean 7 ± 2 yr) postmenopause and had never used
hormone replacement therapy or discontinued use of hormone replacement therapy ≥1 yr
before the start of the study. The research study and its potential risks and benefits were
explained fully before the subjects provided written informed consent according to the
guidelines of the University of Colorado at Boulder. This study was approved by the
University of Colorado at Boulder Human Research Committee.
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Body composition—Body mass was measured to the nearest 0.1 kg with a medical beam
balance (Detecto, Webb City, MO). Percent body fat was determined by dual-energy X-ray
absorptiometry (Lunar Radiation, Madison, WI). BMI was calculated as weight (kg) divided
by height (m) squared. Minimal waist circumference was measured according to previously
published guidelines (16).
Treadmill exercise test—For assessment of aerobic fitness, subjects performed
incremental treadmill exercise using a modified Balke protocol as previously described (10).
Maximal oxygen consumption (V ̇O2 max) was measured using online computer-assisted
open-circuit spirometry.
Metabolic measurements—Fasting plasma lipid and lipoprotein, glucose, and insulin
concentrations were determined using standard techniques by the clinical laboratory
affiliated with the General Clinical Research Center. Insulin resistance was estimated using
the homeostasis model assessment derived from fasting glucose and insulin concentrations
(18). Plasma concentrations of oxidized low-density lipoprotein (oxLDL), C-reactive protein
(CRP), and asymmetric dimethylarginine (ADMA) were determined by enzyme
immunoassay (33).
Intra-arterial infusion protocols—All measurements were performed in a temperature-
controlled room between 7 and 10 AM after a 12-h overnight fast. Under strict aseptic
conditions, a 5-cm, 20-gauge catheter was inserted into the brachial artery of the
nondominant arm under local anesthesia (1% lidocaine). Forearm blood flow (FBF) was
measured in the experimental (nondominant) and the contralateral (dominant) forearm using
strain-gauge venous occlusion plethysmography (D. E. Hokanson) as previously described
(9). FBF responses are presented in milliliters per 100 milliliters of forearm volume per
minute. The total amount of blood flow across the forearm in response to each agonist was
calculated as the area under each curve above baseline with use of a trapezoidal model.
Before the beginning of the study, permission was obtained from the US Food and Drug
Administration to administer methacholine, bradykinin, substance P, and NG-monomethyl-L-
arginine (L-NMMA) to humans.
Protocol 1—In 23 of the 42 normal-weight (BMI = 23.4 ± 0.4 kg/m2, 11 men and 12
women) and 24 of the 44 overweight/obese (BMI = 30.3 ± 0.7 kg/m2, 15 men and 9 women)
subjects, endothelium-dependent vasodilation was assessed by FBF responses to incremental
doses of acetylcholine (IOLAB Pharmaceuticals, Duluth, GA), methacholine (Clinalfa),
bradykinin (Clinalfa), substance P (Clinalfa), and isoproterenol (Isuprel, Abbott
Laboratories). FBF response to sodium nitroprusside (Nitropress, Abbott Laboratories) was
used to assess endothelium-independent vasodilation. Acetylcholine was infused at 4.0, 8.0,
and 16.0 µg · 100 ml tissue−1 · min−1, methacholine at 0.15, 0.30 and 1.0 µg · 100 ml
tissue−1 · min−1, bradykinin at 12.5, 25.0, and 50.0 ng · 100 ml tissue−1 · min−1, substance P
at 75, 150, and 300 pg · 100 ml tissue−1 · min−1, isoproterenol at 5, 10, and 20 ng · 100 ml
tissue−1 · min−1, and sodium nitroprusside at 1.0, 2.0, and 4.0 µg · 100 ml tissue−1 · min−1.
These doses of acetylcholine, methacholine, bradykinin, substance P, and isoproterenol have
been shown to elicit comparable increases in FBF in healthy adults (5, 9, 20). Each dose was
infused for ~5 min, and sufficient time (~20 min) was allowed for FBF to return to resting
levels between drug infusions. To avoid an order effect, the sequence of drug administration
was randomized.
Protocol 2—FBF responses to acetylcholine were determined before and after
administration of the endothelial NO synthase (eNOS) inhibitor L-NMMA(Clinalfa). These
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studies were performed in 19 normal-weight (BMI = 23.3 ± 0.4 kg/m2, 10 men and 9
women) and 20 overweight/obese (BMI = 30.2 ± 0.9 kg/m2, 13 men and 7 women) subjects
who did not participate in protocol 1. After acetylcholine was infused at the doses noted
above and blood flow was allowed to return to resting levels, L-NMMA was infused at 2.5
mg · 100 ml tissue−1 · min−1 for 5 min. Immediately thereafter, the acetylcholine dose
response was repeated with the continuous infusion of L-NMMA.
Statistical Analysis
Differences in subject baseline characteristics and area under the curve data were
determined by ANOVA. Group differences in FBF responses to each vasoactive drug were
determined by repeated-measures ANOVA. Because there were no significant sex
differences with respect to the main effect of overweight/obesity on any of the key outcome
variables, the data were pooled and are presented together. Also, because there were no
significant differences in the responses to the vasoactive agents between the overweight
(BMI = 27–29.9 kg/m2) and obese (BMI ≥ 30 kg/m2) adults, the groups were combined and
referred to as overweight/ obese. The data were analyzed using JMP 6 statistical software
(SAS, Cary, NC). Values are means ± SE. Statistical significance was set a priori at P <
0.05.
RESULTS
Table 1 presents selected subject characteristics. By design, body mass, BMI, and waist
circumference were higher (P < 0.01) in the overweight/obese subjects than normal-weight
controls. In addition, although well within clinically normal levels, plasma triglyceride,
glucose, and insulin concentrations were higher in the obese subjects. Circulating
concentrations of ADMA were not different, but CRP and oxLDL levels were higher in the
overweight/obese subjects than normal-weight controls.
Protocol 1: FBF Responses to Acetylcholine, Methacholine, Bradykinin, Substance P,
Isoproterenol, and Sodium Nitroprusside
Resting FBF in the noninfused arm and mean arterial pressure remained constant throughout
the infusion protocols and were not significantly different between the groups. Blood flow in
the infused arm returned to baseline levels after the infusion of each agonist and was not
significantly different between the groups.
Acetylcholine—Figure 1 shows the FBF responses to acetylcholine in the normal-weight
and overweight/obese groups. The overweight/obese subjects demonstrated a markedly
blunted vasodilator response to acetylcholine. The increase in the FBF response to
acetylcholine was ~25% less (P < 0.01) in the overweight/obese subjects (from 4.3 ± 0.2 to
11.4 ml · 100 ml tissue−1 · min−1) than normal-weight controls (from 4.5 ± 0.2 to 15.4 ml ·
100 ml tissue−1 · min−1). As a result, total FBF to acetylcholine (area under the FBF curve)
was ~40% lower in the overweight/obese subjects than normal-weight controls (50 ± 5 vs.
79 ± 4 ml/100 ml tissue).
Methacholine—Methacholine was administered to 22 of the 23 normal-weight controls
and 21 of the 24 overweight/obese subjects because of drug availability. Similar to
acetylcholine, FBF responses to methacholine were significantly related to differences in
adiposity (Fig. 2). The FBF response to methacholine was ~25% lower (P < 0.01) in the
overweight/obese subjects (from 4.2 ± 0.2 to 12.7 ± 0.6 ml · 100 ml tissue−1 · min−1) than
normal-weight controls (from 4.6 ± 0.2 to 17.3 ± 0.6 ml · 100 ml tissue−1 · min−1). In
addition, total FBF to methacholine was ~30% lower (P < 0.05) in the overweight/obese
subjects than normal-weight controls (55 ± 4 vs. 86 ± 5 ml/100 ml tissue).
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Bradykinin—FBF responses to bradykinin are shown in Fig. 3. In response to bradykinin
stimulation, FBF was ~20% lower (P < 0.01) in the overweight/obese subjects (from 4.1 ±
0.3 to 12.9 ± 0.7 ml · 100 ml tissue−1 · min−1) than normal-weight controls (from 4.6 ± 0.2
to 16.4 ± 0.6 ml · 100 ml tissue−1 · min−1). Consequently, total FBF to bradykinin was lower
(~25%, P < 0.05) in the overweight/obese subjects than normal-weight controls (62 ± 5 vs.
85 ± 4 ml/100 ml tissue).
Substance P—Figure 4 shows the FBF responses to substance P in the normal-weight and
overweight/obese groups. The obese subjects demonstrated significantly reduced vasodilator
responses to substance P: the FBF response to substance P was ~25% lower in the
overweight/obese subjects (from 4.2 ± 0.2 to 10.6 ± 0.6 ml · 100 ml tissue−1 · min−1) than
normal-weight controls (from 4.6 ± 0.2 to 13.4 ± 0.8 ml · 100 ml tissue−1 · min−1). Total
FBF to substance P was ~35% less in the overweight/obese subjects than normal-weight
controls (37 ± 4 vs. 57 ± 5 ml/100 ml tissue).
Isoproterenol—Similar to acetylcholine, methacholine, bradykinin, and substance P,
forearm vascular responses to isoproterenol were diminished in the overweight/obese
subjects (Fig. 5). The increase in the FBF response to isoproterenol was ~25% lower (P <
0.01) in the obese subjects (from 4.4 ± 0.2 to 13.8 ± 0.8 ml · 100 ml tissue−1 · min−1) than
normal-weight controls (from 4.7 ± 0.2 to 16.9 ± 0.8 ml · 100 ml tissue−1 · min−1). Total
FBF to isoproterenol was significantly (~25%) less in the overweight/obese subjects than
normal-weight controls (62 ± 4 vs. 82 ± 6 ml/100 ml tissue).
Sodium nitroprusside—There were no significant differences between the groups in the
FBF responses to sodium nitroprusside (Fig. 6).
Protocol 2: Effects of L-NMMA on FBF Responses to Acetylcholine
Consistent with our findings in protocol 1, FBF responses to acetylcholine were significantly
lower in the overweight/obese subjects (from 4.3 ± 0.2 to 11.1 ± 0.7 ml · 100 ml tissue−1 ·
min−1) than normal-weight controls (from 4.6 ± 0.3 to 14.2 ± 0.9 ml · 100 ml tissue−1 ·
min−1). L-NMMA produced similar reductions (~30%) in FBF at baseline in the overweight/
obese subjects (from 4.2 ± 0.2 to 2.6 ± 0.2 ml · 100 ml tissue−1 · min−1) and normal-weight
controls (from 4.3 ± 0.2 to 2.7 ± 0.2 ml · 100 ml tissue−1 · min−1). Infusion of L-NMMA
significantly blunted the acetylcholine-mediated vasodilator response in both groups (Fig.
7). The magnitude of the reduction (~20%) in FBF was not significantly different between
the overweight/obese subjects and normal-weight controls.
DISCUSSION
It is well established that the forearm vasodilator response to acetylcholine and
methacholine is significantly impaired in overweight and obese adult humans (23, 30, 31).
The results of the present study confirm and extend these findings, inasmuch as we
demonstrate for the first time that FBF responses to other endothelial agonists are also
significantly impaired with increased adiposity. Indeed, in addition to acetylcholine and
methacholine, forearm vasodilation to bradykinin, substance P, and isoproterenol was
substantially lower (~30%) in overweight/obese adults than their normal-weight peers.
Moreover, the results of the present study suggest that impaired endothelium-dependent
vasodilation with increased adiposity is not due to diminished NO production.
To comprehensively assess the influence of overweight/ obesity on endothelium-dependent
vasodilation in conscious humans, we determined the FBF responses to a variety of
endothelial agonists that act via different endothelial cell surface receptors, intracellular
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membrane-bound G proteins, and signal transduction pathways (27). Acetylcholine and
methacholine are muscarinic receptor agonists that stimulate the phospholipase C-
phosphatidylinositol-Ca2+ signaling pathway, via the intracellular membrane-bound
pertussis toxin-sensitive G protein, leading to increased intracellular Ca2+ and the activation
of eNOS and, in turn, production and subsequent release of NO (4, 27). Similar to
acetylcholine and methacholine, bradykinin stimulates the phospholipase C-phosphatidyl-
inositol-Ca2+ intracellular signal transduction pathway; however, this is mediated through
B2-kininergic receptors coupled to a pertussis toxin-insensitive G protein (3). Substance P
and acetylcholine share the same G protein signaling pathway, but substance P interacts with
tachykinin receptors on the endothelial cell surface (26). Inasmuch as acetylcholine,
methacholine, substance P, and bradykinin share the same phospholipase C-
phosphatidylinositol-Ca2+ intracellular signal transduction pathway, it is possible that
impaired Ca2+ release may contribute to the impaired responses. However, isoproterenol is a
β-adrenoceptor agonist that stimulates vasorelaxation, in part, by activating the adenylyl
cyclase pathway, resulting in cAMP activation of eNOS (5). Thus, in the present study,
regardless of the agonist administered, endothelium-dependent vasodilation was
significantly reduced in the overweight/obese subjects compared with normal-weight
controls. Moreover, the magnitude of impairment in vasodilation was similar among the
agonists, suggesting a general endothelial vasomotor abnormality, rather than a specific
endothelial receptor or signal transduction pathway defect. Consistent with this postulate, we
recently reported that obesity-related impairment in acetylcholine-mediated vasodilation
with overweight/obesity is not due to reduced muscarinic receptor responsiveness or
sensitivity (32).
The mechanisms responsible for this general dysfunction in agonist-mediated endothelium-
dependent vasodilation in overweight/obese adults are not clear. All the endothelial agonists
used in the present study stimulate vasodilation, at least in part, by the activation of eNOS
and subsequent production of NO. Overweight and obesity are conditions characterized by
increased oxidative stress and inflammatory burden (12, 15). Increased oxidative stress and
systemic inflammation have been shown to have unfavorable effects on stimulated
endothelial NO bioavailability (37). Consistent with previous work (12, 15), our overweight/
obese subjects demonstrated higher circulating plasma concentrations of oxLDL and CRP,
specific markers of oxidative and inflammatory stress, respectively. Thus a reduction in NO
bioavailability would be a logical mechanism underlying the global impairment in
vasodilator capacity in the overweight/obese subjects. However, the results of the present
study do not support this postulate. In response to infusion of acetylcholine + L-NMMA, we
observed almost identical reductions in forearm vasodilation in the normal-weight controls
and overweight/obese subjects, suggesting that the contribution of NO to acetylcholine-
mediated vasodilation is preserved with increased adiposity. In addition, we observed no
differences in circulating levels of the endogenous eNOS inhibitor ADMA or resting FBF
responses to L-NMMA between the overweight/obese subjects and normal-weight controls.
Consistent with our findings, Nielsen et al. (22) reported similar FBF responses to L-NMMA
in a comparison of young normal-weight and upper body-obese men. Complementing these
findings, a recent in vitro study involving endothelial cells isolated from normal-weight and
overweight/obese adults revealed no group differences in eNOS protein expression (28).
Thus, taken together, these data suggest that adiposity-related endothelial vasodilator
dysfunction is not due to impaired eNOS activity or NO production.
It is possible that elevated vasoconstrictor tone may blunt endothelial vasodilator capacity in
overweight/obese adults. For example, endothelin-1 (ET-1)-mediated vasoconstriction has
been reported to be elevated in overweight/obese adults. ET-1, which is produced primarily
by vascular endothelial cells, is one of the most potent endogenous vasoconstrictor peptides
(36). Mather et al. (17) showed that ET-1-mediated vasoconstrictor tone is higher in
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overweight/obese than normal-weight adults and that this increase in vasoconstrictor activity
contributes to the endothelial vasodilator dysfunction associated with increased body
fatness. Specifically, they demonstrated that blockade of the ETA receptor restored leg blood
flow responses to methacholine in overweight and obese adults to levels similar to that of
normal-weight controls. In addition, angiotensin II-stimulated forearm vasoconstriction has
been reported to be higher in obese men (22). Thus an increase in endothelial
vasoconstrictor tone resulting in limited vasodilator capacity is a tenable hypothesis to
account for the general impairment in endothelium-dependent vasodilation in the
overweight/obese adults.
From a clinical perspective, it is important to emphasize that there were no significant
differences in the FBF responses to any of the endothelial agonists (or sodium nitroprusside)
between the overweight (mean BMI = 27.7 ± 0.3 kg/m2) and obese (BMI = 33.4 ± 0.8 kg/
m2) subjects within the overweight/obese group. Indeed, the peak FBF response to
acetylcholine (12.3 ± 0.7 vs. 10.4 ± 1.0 µg · 100 ml tissue−1 · min−1), methacholine (12.3 ±
0.8 vs. 12.9 ± 0.8 µg · 100 ml tissue−1 · min−1), bradykinin (13.2 ± 0.5 vs. 11.7 ± 1.0 µg ·
100 ml tissue−1 · min−1), substance P (11.3 ± 0.9 vs. 9.9 ± 0.8 ml/100 ml tissue), and
isoproterenol (14.3 ±1.0 vs. 13.1 ± 1.0 ml/100 ml tissue) was similar between the groups,
irrespective of the marked difference in BMI. These data indicate that the impaired
endothelial vasodilator function commonly observed with obesity is apparent in the
overweight state. This finding complements a previous study from our laboratory (34), in a
comparable study population, demonstrating similar levels of endothelial fibrinolytic
dysfunction in overweight and obese subjects compared with normal-weight adults. Thus
increased adiposity resulting in an overweight or obese body status classification is
associated with unfavorable changes in vascular endothelial function. Inasmuch as ~65% of
the US population is overweight (13) and endothelial vasodilator and fibrinolytic
dysfunction are key antecedents to cardiovascular disease and acute vascular events (19, 21,
25, 29), it is imperative that interventions aimed at reducing adiposity and improving
endothelial function not only target obese adults but also those who are mild to moderately
overweight.
Three experimental considerations regarding this study should be mentioned. 1) Considering
our cross-sectional study design, we cannot dismiss the possibility that genetic and/or
lifestyle behaviors may have influenced the results of our group comparisons. To minimize
the influence of lifestyle behaviors, all subjects were nonsmokers, were not currently taking
medication that could influence endothelium-dependent vasodilation, and did not differ in
habitual physical activity. In addition, we studied carefully screened normal-weight and
overweight/ obese adults to eliminate the confounding effects of clinically overt
cardiovascular and metabolic disease. 2) Although we determined the influence of
overweight/obesity on forearm endothelium-dependent vasodilation responses to a number
of agonists, the role of NO in the vasodilator responses was only assessed using L-NMMA
with acetylcholine. Inasmuch as the contribution of NO to endothelium-mediated
vasodilation can vary substantially depending on the agonist used, we cannot confidently
infer from our results similar findings among the other agents. For example, up to 70% of
the forearm vasodilation induced by substance P has been shown to be NO mediated,
compared with 30–40% for acetylcholine (5, 8, 20). It is possible that overweight/obesity-
related differences in NO-mediated vasodilation may emerge with agonists that are
predominantly NO dependent, such as substance P. 3) The results of the present study
pertain only to the forearm vasculature. Although acetylcholine- and methacholine-mediated
endothelium-dependent vasodilation has been shown to be impaired in the coronary and
femoral arteries of overweight/obese adults (1, 31), it is unknown whether the extent of
dysfunction observed in the forearm in response to various agonists is similar to that in other
vascular beds.
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In conclusion, the results of the present study demonstrate that increased adiposity is
associated with profound impairment in endothelium-dependent vasodilation that extends
beyond muscarinic receptor agonists. Regardless of the endothelial agonist employed,
forearm vasodilator capacity is markedly lower in overweight/obese than normal-weight
adults. Moreover, the impairment in endothelial vasodilation with overweight/obesity
appears to be independent of NO bioavailability. Clinically, it is important to emphasize that
the degree of endothelial vasodilator dysfunction observed with obesity is evident in the
overweight state, suggesting that any excess adiposity is associated with impaired
endothelial vasodilator function.
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Forearm blood flow (FBF; A) responses and total FBF (area under the curve; B) to
acetylcholine in normal-weight and overweight/obese groups. Values are means ± SE. *P <
0.05 vs. normal weight.
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FBF responses (A) and total FBF (area under the curve; B) to methacholine in normal-
weight and overweight/obese groups. Values are means ± SE. *P < 0.05 vs. normal weight.
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FBF responses (A) and total FBF (area under the curve; B) to bradykinin in normal-weight
and overweight/obese groups. Values are means ± SE. *P < 0.05 vs. normal weight.
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FBF responses (A) and total FBF (area under the curve; B) to substance P in normal-weight
and overweight/obese groups. Values are means ± SE. *P < 0.05 vs. normal weight.
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FBF responses (A) and total FBF (area under the curve; B) to isoproterenol in normal-
weight and overweight/obese groups. Values are means ± SE. *P < 0.05 vs. normal weight.
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FBF responses (A) and total FBF (area under the curve; B) to sodium nitroprusside in
normal-weight and overweight/obese groups. Values are means ± SE.
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FBF responses and total FBF (area under the curve) to acetylcholine in the absence and
presence of the nitric oxide (NO) synthase inhibitor NG-monomethyl-L-arginine (L-NMMA)
in normal-weight and overweight/obese groups. Values are means ± SE *P < 0.05 vs. saline.
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Age, yr 54±1 54±1
Sex, M/F 21/21 28/16
Body mass, kg 69.9±1.7 90.8±2.2*
Body fat, % 28.3±1.0 36.0±1.2*
BMI, kg/m2 23.4±0.3 30.3 ±0.6*
Waist circumference, cm 81.8±1.4 100.7±2.1*
BP, mmHg
  Systolic 117±2 122±1*
  Diastolic 76±1 78±1
Max O2 uptake, l/min 2.3±0.1 2.5±0.1
Total cholesterol, mmol/l 5.1 ±0.6 5.2±1.1
LDL-C, mmol/l 3.2±0.6 3.3±0.9
HDL-C, mmol/l 1.4±0.3 1.2±0.3
TG, mmol/l 1.1±0.5 1.4±0.7*
Glucose, mmol/l 4.9±0.5 5.2±0.5*
Insulin, pmol/l 27.9±1.9 41.7±3.0*
HOMA-IR 1.0±0.1 1.6±0.1*
ADMA, µmol/l 0.56±0.03 0.50±0.04
CRP, mg/l 0.9±0.2 3.2±0.5*
oxLDL, U/l 45.6±1.9 55.9±2.7*
Values are means ± SE. BMI, body mass index; BP, blood pressure; HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TG, triglycerides;
HOMA-IR, homeostasis model assessment of insulin resistance; ADMA, asymmetric dimethylarginine; CRP, C-reactive protein; oxLDL, oxidized
LDL.
*P < 0.05 vs. normal weight.
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